Blood Cancer Diagnostics Market Research Report Defines the Growth and Increasing Size in Global Health Industry through 2017 to 2022

Dublin, Ireland, 2018-Jul-23 — The global market for blood cancer diagnostics is anticipated to witness significant impact from diagnosis-associated patient compliance trials. Positive attitudes of patients towards certain diagnosis alternatives is decisive in changing future undertakings. Prominent diagnostic tools are likely to be replaced with their upgraded variants. The report has highlighted the influence of government undertakings in offering a better compliance for diagnosis of blood cancer patients.

Key players in the global blood cancer diagnostics market are collaborating with regional health ministries and medical administrators for gauging the impact of therapeutic diagnosis on blood cancer patients. Such cooperative efforts are of paramount importance in the global blood cancer diagnostics market, where overlooking the plausible aftereffects of diagnostic procedures can cost lives.

Request a Free Sample Report Here – https://www.factmr.com/connectus/sample?flag=S&rep_id=47

Blood cancer diagnostics can be defined as the wide range of screening & diagnosis tests associated with blood cancers such as lymphoma, leukemia and myeloma. Bone marrow examination, blood sample tests, complete blood count tests, flow cytometry, cupping therapy and genetic testing are prominent procedures in the diagnosis of blood cancer.

Increase in the prevalence of oncological diseases and technological advancements in diagnostics are positively impacting the global blood cancer diagnostics market. Focus on detecting cancer at an early stage through molecular and RNA/DNA testing can widely improve the diagnosis. As spending on healthcare witnesses a gradual increase in developing countries, the overall blood cancer diagnostics market is projected to grow at a steady rate during the forecast period 2017-2022. According to FactMR’s analysis, the global blood cancer diagnostics market is projected to grow at a steady CAGR during the forecast period.

FactMR’s report offers market analysis and forecast on the global blood cancer diagnostics market on the basis of test type. Liquid biopsy is another test type that remains widely used among end-users. Studies have shown that liquid biopsy can overcome challenges related to intra- and inter-tumor heterogeneity. The research was carried out at Harvard Medical School and Massachusetts General Hospital Cancer Center. Inclusion of liquid biopsy can help in identifying resistance alternations in patients with advanced cholangiocarcinoma. On account of growing preference for liquid biopsy, this segment is projected to increase at a CAGR of over 10% through 2022.

View Full Report Here – https://www.factmr.com/report/47/blood-cancer-diagnostics-market

By end-users, hospital associated labs account for a significant percentage of the global blood cancer diagnostics market. Valued at over US$ 136 million in 2017, the hospital associated labs segment is projected to surpass US$ 180 million in revenues by 2022. Demand from hospital associated labs segment is projected to grow at a steady CAGR during the forecast period.

Demand for blood cancer diagnostics is also significant from the independent diagnostic laboratories segment. According to FactMR’s research, the independent diagnostics laboratories segment is projected to grow steadily through 2022. Cancer research institutes are also a key end-user, and demand from this segment is projected to grow at healthy CAGR through 2022.

Competition Tracking

The key companies profiled in FactMR’s research include Abbott Laboratories, Roche Holding A.G., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Luminex Corporation, Myriad Genetics Inc., NanoString Technologies Inc, NeoGenomics Laboratories, Inc., Siemens AG, Quest Diagnostics Incorporated, Qiagen N.V., Agilent Technologies, Biotheranostics, Inc, Almac Group Limited, and GeneNews Limited.

Overall, the global blood cancer diagnostics market is anticipated to witness steady growth through 2022. The market will continue to be influenced by regulatory policies and guidelines.

Table of Contents

Chapter 1. Global Blood Cancer Diagnostics Market – Executive Summary. 12

Chapter 2. Global Blood Cancer Diagnostics Market Overview. 14

2.1. Introduction. 14

2.1.1. Global Blood Cancer Diagnostics Market Taxonomy. 14

2.1.2. Global Blood Cancer Diagnostics Market Definition. 14

2.2. Global Blood Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022. 15

2.2.1. Global Blood Cancer Diagnostics Market Y-o-Y Growth. 15

2.3. Global Blood Cancer Diagnostics Market Dynamics. 15

2.3.1. Drivers. 15

2.3.2. Restraints. 16

2.3.3. Trends. 16

2.4. Supply Chain. 16

2.5. Epidemiology. 16

2.6. List of Distributors. 16

2.7. Average Pricing Analysis. 17

2.8. Regulations. 17

Continued……………….

If You Need This Useful Report Then Buy This Report Here – https://www.factmr.com/checkout/47/S

About FactMR

FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized Sports market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us –

FactMR
Suite 9884
27 Upper Pembroke Street, Dublin 2, Ireland
Telephone @ +353-1-6111-593
Email: sales@factmr.com
Website: https://www.factmr.com/